The EPS miss and widening losses are negative, but the strong cash position and Phase 3 Duchenne trial progress provide a floor. Watch for FDA guidance on accelerated approval for SGT-003 and initial FALCON data by year-end 2026 as potential catalysts.
Price Chart
Executive Summary
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $56.7M from $39.3M a year ago. The company highlighted Phase 3 Duchenne trial initiation and a strong cash position of $380.7M extending into H1 2028, but the earnings miss and rising R&D costs overshadow pipeline progress.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.53 missed consensus of -$0.44 by 20.9%
- Net loss widened to $56.7M from $39.3M in Q1 2025
- Cash, cash equivalents and securities totaled $380.7M as of March 31, 2026, up from $187.9M at year-end 2025
- R&D expenses rose to $46.1M from $30.9M, driven by SGT-003 manufacturing and clinical costs
- First participant dosed in Phase 3 IMPACT DUCHENNE trial for SGT-003
- 47 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial as of May 11, 2026
- Two participants dosed in Phase 1b FALCON trial for Friedreich's ataxia; no serious adverse events
- Cash runway expected into H1 2028
Financial Impact
EPS miss of 20.9% vs consensus; net loss increased 44.4% YoY to $56.7M
Risk Factors
- Continued cash burn with no near-term revenue; R&D costs may rise further
- Regulatory setbacks or delays in SGT-003 accelerated approval pathway
- Competition from other Duchenne gene therapies (e.g., Pfizer, Sarepta)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293411 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | S-3ASR | $8.39 $10.25 | ▲ +22.17% | ▲ +22.57% | $6.88 (−18.06%) |
May 12, 2026 20w ago | Press Release | $7.38 $7.22 | ▲ +2.17% | ▲ +1.56% | $6.88 (+6.84%) |
May 7, 2026 21w ago | Press Release | $7.07 $6.85 | ▼ −3.11% | ▼ −6.25% | $6.88 (−2.76%) |
Apr 23, 2026 23w ago | DEFA14A | $7.92 $6.50 | ▼ −17.93% | ▼ −21.96% | $6.88 (−13.19%) |
Apr 10, 2026 24w ago | 8-K | $8.39 $7.68 | ▼ −8.46% | ▼ −16.19% | $6.88 (−18.06%) |
Apr 1, 2026 26w ago | EFFECT | $7.38 $7.05 | ▲ +4.47% | ▲ +14.19% | $6.88 (+6.84%) |
Mar 19, 2026 28w ago | Press Release | $7.03 $8.49 | ▲ +20.77% | ▲ +11.45% | $6.88 (−2.20%) |
Mar 12, 2026 29w ago | 8-K | $7.71 $8.02 | ▲ +4.02% | ▲ +2.05% | $6.88 (−10.83%) |
Mar 11, 2026 29w ago | Press Release | $7.72 $8.10 | ▲ +4.99% | ▲ +4.47% | $6.88 (−10.89%) |
Mar 6, 2026 30w ago | Press Release | $6.75 $7.74 | ▲ +14.67% | ▲ +16.71% | $6.88 (+1.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access